Revere Asset Management Inc Acquires New Shares in Liquidia Corporation $LQDA

Revere Asset Management Inc acquired a new stake in Liquidia Corporation (NASDAQ:LQDA) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 9,201 shares of the company’s stock, valued at approximately $317,000. Liquidia makes up approximately 0.1% of Revere Asset Management Inc’s portfolio, making the stock its 24th biggest position.

Several other institutional investors and hedge funds have also recently made changes to their positions in LQDA. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in shares of Liquidia by 4.7% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 37,681 shares of the company’s stock valued at $556,000 after acquiring an additional 1,700 shares in the last quarter. Goldman Sachs Group Inc. raised its holdings in shares of Liquidia by 10.7% in the first quarter. Goldman Sachs Group Inc. now owns 861,231 shares of the company’s stock valued at $12,703,000 after acquiring an additional 82,955 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its holdings in shares of Liquidia by 15.2% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 121,756 shares of the company’s stock valued at $1,796,000 after acquiring an additional 16,022 shares in the last quarter. Creative Planning raised its holdings in shares of Liquidia by 40.7% in the second quarter. Creative Planning now owns 26,840 shares of the company’s stock valued at $334,000 after acquiring an additional 7,765 shares in the last quarter. Finally, Legal & General Group Plc raised its holdings in shares of Liquidia by 13.4% in the second quarter. Legal & General Group Plc now owns 94,152 shares of the company’s stock valued at $1,174,000 after acquiring an additional 11,111 shares in the last quarter. 64.54% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Liquidia

In other news, Director Stephen M. Bloch sold 318,893 shares of the business’s stock in a transaction dated Monday, May 11th. The stock was sold at an average price of $50.23, for a total transaction of $16,017,995.39. Following the sale, the director owned 1,870,042 shares in the company, valued at approximately $93,932,209.66. The trade was a 14.57% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Roger Jeffs sold 32,744 shares of the business’s stock in a transaction dated Monday, April 13th. The stock was sold at an average price of $38.37, for a total value of $1,256,387.28. Following the sale, the chief executive officer owned 1,137,599 shares in the company, valued at $43,649,673.63. The trade was a 2.80% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 1,047,713 shares of company stock worth $46,156,003 over the last quarter. Insiders own 25.60% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts recently weighed in on LQDA shares. Needham & Company LLC lifted their price objective on Liquidia from $54.00 to $70.00 and gave the company a “buy” rating in a report on Monday, May 11th. Lifesci Capital upgraded Liquidia to a “strong-buy” rating in a report on Thursday, March 5th. Raymond James Financial reiterated a “strong-buy” rating on shares of Liquidia in a research note on Thursday, March 5th. Wells Fargo & Company lifted their target price on Liquidia from $51.00 to $62.00 and gave the company an “overweight” rating in a research note on Tuesday, May 12th. Finally, Zacks Research upgraded Liquidia from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, May 5th. Three investment analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating and two have issued a Sell rating to the stock. Based on data from MarketBeat, Liquidia presently has an average rating of “Moderate Buy” and an average price target of $49.33.

Liquidia Price Performance

LQDA opened at $60.98 on Tuesday. The business’s 50-day moving average is $42.53 and its two-hundred day moving average is $37.56. Liquidia Corporation has a 1 year low of $11.85 and a 1 year high of $62.30. The company has a debt-to-equity ratio of 1.18, a current ratio of 2.22 and a quick ratio of 2.03. The firm has a market capitalization of $5.42 billion, a PE ratio of 435.60 and a beta of 0.41.

Liquidia (NASDAQ:LQDA) last posted its earnings results on Monday, May 11th. The company reported $0.52 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.41 by $0.11. Liquidia had a return on equity of 46.82% and a net margin of 7.74%.The company had revenue of $132.87 million for the quarter, compared to analyst estimates of $119.44 million. The company’s revenue for the quarter was up 4187.1% compared to the same quarter last year. Research analysts anticipate that Liquidia Corporation will post 2.97 earnings per share for the current fiscal year.

About Liquidia

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).